Distribution, levels, and activation of MEK1 in Alzheimer's disease

Journal of Neurochemistry

Volumn 86, Issue 1, 2003, Pages 136-142

  Zhu, Xiongwei ^a   Sun, Zheng ^a   Lee, Hyoung gon ^a   Siedlak, Sandra L ^a   Perry, George ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Cell cycle control; Extracellular signal regulated kinase; MAPK ERK kinase 1; Nuclear traffic; Oxidative stress

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1;

ALZHEIMER DISEASE; ARTICLE; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PATHOGENESIS; PRIORITY JOURNAL;

ACTIVE TRANSPORT, CELL NUCLEUS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CELL NUCLEUS; CYTOPLASMIC GRANULES; ENZYME ACTIVATION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE 1; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEURONS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 0038308492     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01820.x     Document Type: Article

References (41)

1. Adachi M., Fukuda M. and Nishida E. (2000) Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J. Cell Biol. 148, 849-856.
2. Blanchard B. J., devi Raghunandan R., Roder H. M. and Ingram V. M. (1994) Hyperphosphorylation of human TAU by brain kinase PK40erk beyond phosphorylation by cAMP-dependent PKA: relation to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200, 187-194.
3. Braak H. and Braak E. (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
4. Derkinderen P., Enslen H. and Girault J. A. (1999) The ERK/MAP-kinases cascade in the nervous system. Neuroreport 10, R24-R34.
5. Desdouits-Magnen J., Desdouits F., Takeda S., Syu L. J., Saltiel A. R., Buxbaum J. D., Czernik A. J., Nairn A. C. and Greengard P. (1998) Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J. Neurochem. 70, 524-530.
6. Dineley K. T., Westerman M., Bui D., Bell K., Ashe K. H. and Sweatt J. D. (2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 21, 4125-4133.
7. English J. D. and Sweatt J. D. (1997) A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J. Biol. Chem. 272, 19103-19106.
8. Ferrer I., Blanco R., Carmona M., Puig B., Barrachina M., Gomez C. and Ambrosio S. (2001a) Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J. Neural Transm. 108, 1383-1396.
9. Ferrer I., Blanco R., Carmona M., Ribera R., Goutan E., Puig B., Rey M. J., Cardozo A., Vinals F. and Ribalta T. (2001b) Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 11, 144-158.
10. Flood D. G., Finn J. P., Walton K. M., Dionne C. A., Contreras P. C., Miller M. S. and Bhat R. V. (1998) Immunolocalization of the mitogen-activated protein kinases p42MAPK and JNK1, and their regulatory kinases MEK1 and MEK4, in adult rat central nervous system. J. Comp. Neurol. 398, 373-392.
11. Fukuda M., Gotoh I., Gotoh Y. and Nishida E. (1996) Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J. Biol. Chem. 271, 20024-20028.
12. Fukuda M., Gotoh I., Adachi M., Gotoh Y. and Nishida E. (1997) A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase. J. Biol. Chem. 272, 32642-32648.
13. Grewal S. S., York R. D. and Stork P. J. (1999) Extracellular-signal-regulated kinase signalling in neurons. Curr Opin. Neurobiol. 9, 544-553.
14. Hartzler A. W., Zhu X., Siedlak S. L., Castellani R. J., Avila J., Perry G. and Smith M. A. (2002) The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol. Aging 23, 855-859.
15. Holzer M., Rodel L., Seeger G., Gartner U., Narz F., Janke C., Heumann R. and Arendt T. (2001) Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. II. Cytoskeletal proteins and dendritic morphology. Neuroscience 105, 1041-1054.
16. Jaaro H., Rubinfeld H., Hanoch T. and Seger R. (1997) Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc. Natl Acad. Sci. USA 94, 3742-3747.
17. Khachaturian Z. S. (1985) Diagnosis of Alzheimer's disease. Arch. Neurol. 42, 1097-1105.
18. Klein J. A., Longo-Guess C. M., Rossmann M. P., Seburn K. L., Hurd R. E., Frankel W. N., Bronson R. T. and Ackerman S. L. (2002) The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 419, 367-374.
19. Kuperstein F. and Yavin E. (2002) ERK activation and nuclear translocation in amyloid-beta peptide- and iron-stressed neuronal cell cultures. Eur J. Neurosci. 16, 44-54.
20. McShea A., Zelasko D. A., Gerst J. L. and Smith M. A. (1999) Signal transduction abnormalities in Alzheimer's disease: evidence of a pathogenic stimuli. Brain Res. 815, 237-242.
21. Mills J., Laurent Charest D., Lam F., Beyreuther K., Ida N., Pelech S. L. and Reiner P. B. (1997) Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J. Neurosci. 17, 9415-9422.
22. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G. and Berg L. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
23. Nishimura M. et al. (1999) Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat. Med. 5, 164-169.
24. Ortiz J., Harris H. W., Guitart X., Terwilliger R. Z., Haycock J. W. and Nestler E. J. (1995) Extracellular signal-regulated protein kinases (ERKs) and ERK kinase (MEK) in brain: regional distribution and regulation by chronic morphine. J. Neurosci. 15, 1285-1297.
25. Pei J. J., Braak H., An W. L., Winblad B., Cowburn R. F., Iqbal K. and Grundke-Iqbal I. (2002) Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res. Mol. Brain Res. 109, 45-55.
26. Perry G. et al. (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10, 2411-2415.
27. Perry G., Raina A. K., Nunomura A., Wataya T., Sayre L. M. and Smith M. A. (2000) How important is oxidative damage? Lessons from Alzheimer's disease. Free Radic. Biol. Med. 28, 831-834.
28. Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G. and Kokmen E. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308.
29. Raina A. K., Zhu X., Rottkamp C. A., Monteiro M., Takeda A. and Smith M. A. (2000) Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J. Neurosci. Res. 61, 128-133.
30. Rapoport M. and Ferreira A. (2000) PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J. Neurochem. 74, 125-133.
31. Roder H. M., Eden P. A. and Ingram V. M. (1993) Brain protein kinase PK40erk converts TAU into a PHF-like form as found in Alzheimer's disease. Biochem. Biophys. Res. Commun. 193, 639-647.
32. Rosenblum K., Futter M., Voss K., Erent M., Skehel P. A., French P., Obosi L., Jones M. W. and Bliss T. V. (2002) The role of extracellular regulated kinases I/II in late-phase long-term potentiation. J. Neurosci. 22, 5432-5441.
33. Smith M. A., Kutty R. K., Richey P. L., Yan S. D., Stern D., Chader G. J., Wiggert B., Petersen R. B. and Perry G. (1994) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145, 42-47.
34. Stein T. D. and Johnson J. A. (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci. 22, 7380-7388.
35. Wei W., Wang X. and Kusiak J. W. (2002) Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J. Biol. Chem. 277, 17649-17656.
36. Zhu X., Raina A. K. and Smith M. A. (1999) Cell cycle events in neurons. Proliferation or death? Am. J. Pathol 155, 327-329.
37. Zhu X., Castellani R. J., Takeda A., Nunomura A., Atwood C. S., Perry G. and Smith M. A. (2001a) Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing Dev. 123, 39-46.
38. Zhu X., Raina A. K., Rottkamp C. A., Aliev G., Perry G., Boux H. and Smith M. A. (2001b) Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76, 435-441.
39. Zhu X., Rottkamp C. A., Hartzler A., Sun Z., Takeda A., Boux H., Shimohama S., Perry G. and Smith M. A. (2001c) Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem. 79, 311-318.
40. Zhu X., Lee H.-G., Perry G., Raina A. K. and Smith M. A. (2002) The MAPK Pathways in Alzheimer's Disease. Neurosignals 11, 270-281.
41. Zhu X., Ogawa O., Wang Y., Perry G. and Smith M. A. (2003) JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J. Neurochem. 85, 87-93.